Primaxin, Recarbrio(imipenem)
Cilastatin / Imipenem, Primaxin, Recarbrio (imipenem) is a small molecule pharmaceutical. Imipenem was first approved as Primaxin on 1985-11-26. It is used to treat bacterial endocarditis, bacterial infections, enterobacteriaceae infections, infectious bone diseases, and intraabdominal infections amongst others in the USA. It has been approved in Europe to treat gram-negative bacterial infections.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Combinations
Imipenem cilastatin, Primaxin, Recarbrio (discontinued: Imipenem cilastatin, Primaxin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cilastatin sodium
+
Imipenem
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PRIMAXIN | Merck & Co | N-050587 RX | 1985-11-26 | 1 products, RLD, RS |
Show 2 discontinued
Cilastatin sodium
+
Imipenem
+
Relebactam
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RECARBRIO | Merck & Co | N-212819 RX | 2019-07-16 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| imipenem and cilastatin | ANDA | 2024-05-30 |
| imipenem and cilastatin imipenem and cilastatin | ANDA | 2022-10-11 |
| primaxin | ANDA, New Drug Application | 2024-07-05 |
| recarbrio | New Drug Application | 2024-10-28 |
Indications
FDA
EMA
Show 4 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CILASTATIN SODIUM / IMIPENEM / RELEBACTAM, RECARBRIO, MSD MERCK CO | |||
| 2029-07-16 | GAIN | ||
| 2024-07-16 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Cilastatin Sodium / Imipenem / Relebactam, Recarbrio, Msd Merck Co | |||
| 8487093 | 2029-11-19 | DS, DP | U-2586, U-2587, U-2840 |
Clinical
Clinical Trials
107 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | 4 | 11 | 13 | 7 | 6 | 38 |
| Communicable diseases | D003141 | — | — | 2 | 8 | 9 | 3 | 5 | 26 |
| Pneumonia | D011014 | EFO_0003106 | — | 1 | 2 | 7 | 7 | 4 | 21 |
| Bacterial infections | D001424 | — | A49 | 6 | 3 | 3 | 1 | 4 | 15 |
| Urinary tract infections | D014552 | EFO_0003103 | N39.0 | — | 6 | 6 | 1 | 1 | 14 |
| Ventilator-associated pneumonia | D053717 | EFO_1001865 | J95.851 | — | 1 | 4 | 5 | 1 | 11 |
| Critical illness | D016638 | — | — | — | — | 1 | 4 | 5 | 10 |
| Sepsis | D018805 | HP_0100806 | A41.9 | 3 | 2 | 1 | 2 | 3 | 9 |
| Bacterial pneumonia | D018410 | EFO_1001272 | J15.9 | — | 2 | 5 | 1 | — | 8 |
| Intraabdominal infections | D059413 | — | — | — | 3 | 4 | 1 | — | 7 |
Show 21 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pyelonephritis | D011704 | EFO_1001141 | N10-N16 | — | 5 | 4 | — | — | 9 |
| Bacteremia | D016470 | EFO_0003033 | R78.81 | — | — | 2 | — | 1 | 3 |
| Neoplasms | D009369 | — | C80 | — | 2 | 1 | — | 1 | 3 |
| Lung diseases | D008171 | HP_0002088 | J98.4 | — | 1 | 1 | — | 1 | 2 |
| Iatrogenic disease | D007049 | — | — | — | — | 2 | — | — | 2 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | 1 | 1 | — | 1 | 2 |
| Healthcare-associated pneumonia | D000077299 | — | — | — | 1 | 1 | — | — | 2 |
| Abdominal abscess | D018784 | EFO_1001753 | — | — | 1 | 1 | — | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | 1 | — | 1 | 2 |
| Mycobacterium infections | D009164 | — | A31.9 | — | 1 | 1 | — | — | 1 |
Show 10 more
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peritonitis | D010538 | EFO_0008588 | K65 | — | — | — | — | 3 | 3 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 2 | 2 |
| Lung transplantation | D016040 | — | — | — | — | — | — | 2 | 2 |
| Inappropriate prescribing | D057970 | — | — | — | — | — | — | 1 | 1 |
| Continuous renal replacement therapy | D000079664 | — | — | — | — | — | — | 1 | 1 |
| Penicillin resistance | D010403 | — | — | — | — | — | — | 1 | 1 |
| Drug monitoring | D016903 | — | — | — | — | — | — | 1 | 1 |
| Toxemia | D014115 | — | — | — | — | — | — | 1 | 1 |
| High-throughput nucleotide sequencing | D059014 | — | — | — | — | — | — | 1 | 1 |
| Septic shock | D012772 | — | A48.3 | — | — | — | — | 1 | 1 |
Show 11 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Imipenem |
| INN | imipenem |
| Description | Imipenem is a broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup. It has a role as an antibacterial drug. It is a beta-lactam antibiotic allergen and a member of carbapenems. It is a tautomer of an imipenem zwitterion. |
| Classification | Small molecule |
| Drug class | antibacterial antibiotics, carbapenem derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@@H](O)[C@H]1C(=O)N2C(C(=O)O)=C(SCCNC=N)C[C@H]12 |
Identifiers
| PDB | — |
| CAS-ID | 64221-86-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL148 |
| ChEBI ID | 471744 |
| PubChem CID | 104838 |
| DrugBank | DB01598 |
| UNII ID | Q20IM7HE75 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Primaxin – Merck & Co
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Imipenem
+
Cilastatin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 37,714 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
8,405 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use